Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment.

In the RCT, nominally significant placebo-adjusted differences in LS mean change from baseline to end point on the ADHD-RS-IV were observed in GXR-treated participants, in both subgroups (prior MPH, −9.8 [95% CI −14.6 to −5.1], P <0.001, ES 0.85; stimulant-naïve: −7.6 [95% CI −11.8 to −3.3], P <0.001, ES 0.65).

also in 7,732 other papers